| Grant number: | 17/07314-1 |
| Support Opportunities: | Regular Research Grants |
| Start date: | October 01, 2017 |
| End date: | March 31, 2020 |
| Field of knowledge: | Health Sciences - Dentistry - Dental Clinics |
| Principal Investigator: | Karin Hermana Neppelenbroek |
| Grantee: | Karin Hermana Neppelenbroek |
| Host Institution: | Faculdade de Odontologia de Bauru (FOB). Universidade de São Paulo (USP). Bauru , SP, Brazil |
| City of the host institution: | Bauru |
| Associated researchers: | Ana Lucia Pompeia Fraga de Almeida ; César Augusto Galvão Arrais ; Simone Soares ; Vanessa Migliorini Urban ; Vanessa Soares Lara ; Vinicíus Carvalho Porto |
Abstract
Antimicrobial agents incorporated into temporary denture relines have proven to be effective and viable as denture stomatitis' treatment in studies in vivo and in vitro. This therapeutic approach has the advantage of breaking the cycle of mucosal reinfection, acting on them through the incorporated drugs, which are released gradually over the useful life of these materials. It has been previously demonstrated that, within 14 days, nystatin and chlorhexidine diacetate incorporated into a temporary reliner (Trusoft) were the drugs that had minimal inhibitory concentrations (MICs) for C. albicans biofilm. Furthermore, it was observed that the addition of these MIC drugs resulted in no deleterious effects on the structural, physical and mechanical properties of the material. Despite these advantages, there are no studies with patients on effective incorporation of antifungal MICs in temporary denture reliner as method for denture stomatitis' treatment. Thus, the objective of the present study was to clinically evaluate the addition MICs of antifungal agents for C. albicans biofilm (nystatin and chlorhexidine) on the temporary resilient materials (Trusoft) in denture stomatitis' treatment. Sixty patients with denture stomatitis and users of at least one upper complete denture (CD) will be divided into four groups according to the treatment (n=15): Positive control: conventional topical antifungal agent (Nystatin oral suspension); General control: relining the upper CD with Trusoft; Nis Group: relining the upper CD with Trusoft containing Nystatin in its MIC and CLX Group: relining the upper CD with Trusoft containing the chlorhexidine diacetate in its MCI. The effectiveness of treatments will be evaluated by cytological smear, mycological quantitative cultures obtained from the inner surface of the CD and palatal mucosa of all patients before and after treatment and 15 and 30 days after its suspension. For clinical assessment, palatal photographs will be obtained of all patients at each visit. The data will be analyzed statistically (±=5%). (AU)
| Articles published in Agência FAPESP Newsletter about the research grant: |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |